A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults

NCT ID: NCT07059403

Last Updated: 2025-08-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-19
• Study Completion Date: 2027-04-30

Brief Summary

This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.

Conditions

Chronic Hepatitis B Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Cohort A

Participants will be randomized in a 3:1 ratio to receive 4 doses of either SN2001 or placebo.

Group Type: EXPERIMENTAL

SN2001

Intervention Type: BIOLOGICAL

100 µg, for subcutaneous (SC) injection

Cohort B

Participants will be randomized in a 3:1 ratio to receive 4 doses of either SN2001 or placebo.

Group Type: EXPERIMENTAL

SN2001

Intervention Type: BIOLOGICAL

200 µg, for subcutaneous (SC) injection

Cohort C

Participants will be randomized in a 3:1 ratio to receive 4 doses of either SN2001 or placebo.

Group Type: EXPERIMENTAL

SN2001

Intervention Type: BIOLOGICAL

300 µg, for subcutaneous (SC) injection

Interventions

SN2001

100 µg, for subcutaneous (SC) injection

Intervention Type: BIOLOGICAL

SN2001

200 µg, for subcutaneous (SC) injection

Intervention Type: BIOLOGICAL

SN2001

300 µg, for subcutaneous (SC) injection

Intervention Type: BIOLOGICAL

Other Intervention Names

Placebo; Placebo; Placebo

Eligibility Criteria

Inclusion Criteria

1. Age 18 to 55 years, inclusive.

2. Body mass index (BMI) ≥18.0 kg/m2 and ≤ 32.0 kg/m2.

3. Participants are in good general health as determined by the investigator, based on a medical evaluation including medical history, vital signs, physical examination, 12-lead electrocardiogram, clinical laboratory tests.

4. Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as hysterectomy, bilateral ovariectomy or post-menopause. A postmenopausal state should be confirmed by at least 12 months since last menstrual period and FSH > 40 IU.

5. Women of childbearing potential (WOCBP) may be enrolled in the study if the participant:

• has practiced highly-effective contraception for 28 days prior to first injection, and
• has a negative pregnancy test at Screening, and
• agrees to refrain from ova donation from Screening until 48 weeks after completion of the final injection, and
• practices abstinence as part of her usual and preferred lifestyle, and
• has agreed to continue highly-effective contraception from Screening until 48 weeks after completion of the final injection.

6. Male participants:

• with documented bilateral orchiectomy, or
• agrees to practice abstinence from penile-vaginal intercourse or use condoms from Screening until 48 weeks after completion of the final subcutaneous injection, and
• agrees to refrain from sperm donation from Screening until 48 weeks after completion of the final injection, and
• the highly effective contraceptive methods listed above should also apply to WOCBP partners of male participants for the specified duration, in addition to male condom use, from Screening until 48 weeks after completion of the final injection.

7. Willing to comply with the study requirements and to provide written informed consent.

Exclusion Criteria

1. History of Hepatitis B virus (HBV) infection as evidenced by detection of HBV Surface and Core antigens.

2. Clinical laboratory evidence of active infection with human immunodeficiency virus (HIV) infection, or hepatitis C virus (HCV) infection, or hepatitis A virus (HAV), or hepatitis D virus (HDV), or syphilis and/or any other chronic viral infection.

3. Known exposure (e.g., sexual contact or blood exposure) to HBV within the past 6 weeks.

4. History of HBV vaccination:

• Have not previously been vaccinated in the community for Hepatitis B (Engerix-B or similar), or
• Have received any HBV vaccination (documented evidence of vaccination, or verbal history of vaccination) and a seroprotective Hepatitis B surface antibody (HBsAb) titre <10 milli-international units per milliliter (mIU/mL) at screening, or
• Have received any HBV vaccination (documented evidence of vaccination, or verbal history of vaccination) within 6 months prior to the screening visit, or
• Have HBV vaccination scheduled plan within 48 weeks after the final study drug dosing.

5. Receipt of any investigational drug or vaccine or medical device clinical trial within 3 months or 5 half-lives (whichever is greater) prior to screening.

6. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin greater than or equal to 1.5×ULN, or any other laboratory values considered clinically significant abnormalities and unacceptable by the Investigator at screening.

7. Current or a history of any clinically significant medical illness or medical disorders the investigator considers should exclude including (but not limited to) neurological disease, cardiovascular disease, hepatic or renal disease (such as chronic liver disease), gastrointestinal tract disease, respiratory disease, metabolism, skeletal system diseases or other conditions known to put the subject at significant risk.

8. History of Cancer within 3 years, excluding basal cell carcinoma, squamous cell carcinoma, or cervical intraepithelial neoplasia, which is cured is allowed.

9. Presence of any medical condition that may be associated with impaired immune responsiveness, including diabetes mellitus.

10. History of any severe trauma or major surgical condition within 3 months or planned to undergo surgery during the study period.

11. Presently receiving (or history of receiving), during the preceding 3 months or 5 half-lives (whichever is greater), any medications or other treatments that may adversely affect the immune system such as allergy injections, immune globulin, interferon, immunomodulators, cytotoxic drugs or other drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable). Inhaled and topical corticosteroids, intranasal corticosteroids (e.g. Nasonex for allergic rhinitis) are allowed.

12. Used prescription drugs or vaccines within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug.

13. Used over-the-counter (OTC) medication or herbal supplements, excluding routine vitamins, within 7 days before the first dose of study drug, unless determined by the Investigator and the Sponsor to be not clinically relevant and unlikely to impact on study outcomes. Paracetamol or ibuprofen can be considered an exception for the treatment of headaches or any other pain for eligibility purposes.

14. Participants smoke ≥ 10 cigarettes a day within 3 months before screening, or those who cannot stop using any tobacco products from screening until 24 weeks after the final injection.

15. History or clinical evidence of alcohol abuse, within the 3 months before screening, and unwillingness to abstain from alcohol within 3 weeks after the final study drug dosing. Alcohol abuse is defined as regular weekly intake of more than 14 units for male and 10 units for female (unit: 1 glass of wine [125 mL] = 1 measure of spirits = ½ pint of beer).

16. History or clinical evidence of drug abuse, within the 12 months before screening. Drug abuse is defined as compulsive, repetitive, and/or chronic use of drugs or other substances with or without problems related to their use and/or were stopping or a reduction in dose will lead to withdrawal symptoms.

17. Confirmed positive results from drug of abuse (amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, cocaine, opiates, methylenedioxymethamphetamine, phencyclidine, tetrahydrocannabinol, cotinine, tricyclic anti-depressants) or from the alcohol breath test at screening.

18. History of significant local or systemic reactogenicity (e.g., anaphylaxis, respiratory difficulties, angioedema, injection site necrosis or ulceration).

19. Donated more than 400 mL of blood within 30 days before the first dose of study drug.

20. Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Chimivac INC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Q-Pharm Pty Ltd.

Herston, Queensland, Australia

Site Status: RECRUITING

Countries

Australia

Central Contacts

Clinical Development VP, PhD

Role: CONTACT

contact@chimigen.com

+1-917-439-9820

Facility Contacts

Michael Wong, Dr

Role: primary

m.wong@nucleusnetwork.com.au

0737072720

Other Identifiers

CMG.2001.101

Identifier Type: -

Identifier Source: org_study_id